Bromantane and Tamoxifen Interaction: Avoid | Peptide Database

Join others researching Phenylpiracetam — share findings, ask questions, and learn from real experiences Phenylpiracetam (also known as Phenotropil, Carphedon, or Fonturacetam) is a phenylated derivative of piracetam developed in Russia in 1983, originally for Soviet cosmonauts to enhance cognitive function, physical stamina, and cold tolerance during space missions. The addition of a phenyl group to piracetam's pyrrolidone nucleus fundamentally changes the compound's pharmacological profile -- it crosses the blood-brain barrier more readily, has significantly greater affinity for multiple neurotransmitter systems, and exhibits pronounced psychostimulant and physical performance-enhancing properties absent in piracetam. Phenylpiracetam was approved and marketed in Russia as Phenotropil for cognitive impairment, asthenia, and convulsive disorders until its manufacturer ceased production. It gained notoriety in the sporting world after the World Anti-Doping Agency (WADA) added it to the prohibited substances list following its detection in several Olympic athletes, confirming its reputation as a legitimate performance enhancer. One of its most distinctive properties is the enhancement of cold tolerance, a trait that directly reflects its origins as a cosmonaut support compound and has been demonstrated in animal models of hypothermia. Phenylpiracetam modulates multiple neurotransmitter systems, which accounts for its broad spectrum of cognitive and physical effects. Like other racetams, it acts as a positive allosteric modulator of AMPA receptors, enhancing glutamatergic transmission and facilitating long-term potentiation in hippocampal circuits critical for memory formation. However, unlike piracetam, phenylpiracetam also significantly affects dopaminergic and noradrenergic signaling -- it increases the density of dopamine D1, D2, and D3 receptors and noradrenaline receptors in the striatum and other brain regions, which underpins its stimulant, mood-elevating, and motivation-enhancing properties. It also modulates nicotinic acetylcholine receptors and NMDA-type glutamate receptors, contributing to its procognitive effects. The phenyl group increases lipophilicity, allowing faster and more complete penetration of the blood-brain barrier compared to piracetam. Phenylpiracetam also demonstrates anticonvulsant activity and has been shown to reduce the threshold for cold-induced stress responses, likely through modulation of hypothalamic thermoregulatory circuits and peripheral adrenergic mechanisms. The compound's physical performance-enhancing effects are attributed to increased noradrenergic and dopaminergic tone, enhanced muscular endurance, and reduced perception of effort and fatigue.

Join others researching FGL — share findings, ask questions, and learn from real experiences FGL is a synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule (NCAM). It mimics the interaction between NCAM and fibroblast growth factor receptor 1 (FGFR1), activating downstream signaling cascades that promote synaptic plasticity, neurogenesis, and neuroprotection. Research has primarily been conducted in animal models, where FGL has shown promise for cognitive enhancement, stroke recovery, and neurodegenerative disease models. FGL binds to and activates FGFR1, triggering receptor autophosphorylation and downstream signaling through the MAPK/ERK and PI3K/Akt pathways. This activation promotes long-term potentiation (LTP), enhances synaptic plasticity, stimulates neurogenesis in the hippocampus, and provides neuroprotective effects against excitotoxicity and oxidative stress.